GERN - Geron Corporation
1.66 +0.02 (1.22%)
After hours: 5:17PM EDT
| Previous Close | 1.67 |
| Open | 1.68 |
| Bid | 1.62 x 34100 |
| Ask | 1.70 x 2900 |
| Day's Range | 1.61 - 1.72 |
| 52 Week Range | 1.50 - 6.99 |
| Volume | 2,618,967 |
| Avg. Volume | 8,836,860 |
| Market Cap | 301.14M |
| Beta (3Y Monthly) | 2.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.18 |
| Earnings Date | May 4, 2017 - May 8, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- GlobeNewswire•8 days ago
Report: Developing Opportunities within CorEnergy Infrastructure Trust, Calumet Specialty Products Partners, Iron Mountain, Geron, Bruker, and Loews — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•12 days ago
Geron (GERN) Stock Moves -0.58%: What You Should Know
In the latest trading session, Geron (GERN) closed at $1.72, marking a -0.58% move from the previous day.
- Motley Fool•14 days ago
Here's Why Geron Plummeted 69% in September
The biotech's partner said goodbye. Investors cried.
- Zacks•14 days ago
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
- Motley Fool•14 days ago
Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?
A partner walks away and trial data fails to impress. Here's what's next for these biotech upstarts.
- Zacks•19 days ago
Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs
The biotech sector grabs headlines this week with FDA approvals plus licensing and acquisition pacts.
- Benzinga•23 days ago
Benzinga's Bulls & Bears Of The Week: Apple, GE, IBM, Nike, Tesla And More
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included leaders in e-commerce, smartphones and footwear. Bearish calls included a struggling conglomerate ...
- Motley Fool•24 days ago
2 Stocks That Could Benefit Big From Geron's Stumble
A disappointing decision could mean one fewer competitor for these biotech companies.
- Business Wire•24 days ago
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Geron Corp.
The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (GERN). This investigation concerns whether Geron has violated federal securities laws and/or engaged in other unlawful business practices. On September 27, 2018, Geron announced that “Janssen Biotech, Inc. (Janssen) has terminated the 2014 Collaboration and License Agreement (CLA) with the Company.
- Motley Fool•24 days ago
Why Geron Corporation's Stock Is Sinking, Again
Geron's future is uncertain now that Johnson & Johnson has exited the picture.
- ACCESSWIRE•25 days ago
Stem Cell Companies Moving The Markets
HENDERSON, NV / ACCESSWIRE / September 28, 2018 / One stem cell play we like a lot is BioRestorative Therapies, Inc., (BRTX) a life sciences company focused on stem cell-based therapies. They recently ...
- Zacks•25 days ago
Geron's Stock Plunges as J&J Ends Imetelstat Collaboration
Geron (GERN) announces termination of collaboration with J&J for development of its sole pipeline candidate, imetelstat.
- Motley Fool•25 days ago
Can Geron Corporation Recover From Its Breakup With Johnson & Johnson?
A rebound relationship could save the stock, but will anyone else ask Geron to dance?
- Motley Fool•25 days ago
After Its Disastrous Day, What's Next for Geron Corp.?
The decision by its long-term collaboration partner leaves the company at a crossroads.
- ACCESSWIRE•25 days ago
Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals and Geron
NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Rxi Pharmaceuticals saw its shares soaring on Thursday as the company presented a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference. Geron shares were going in the opposite direction and crashed hard after Wall Street learned that its collaboration with Johnson & Johnson has come to an end. RXi Pharmaceuticals Corporation shares were up a little over 28% at the close on Thursday.
- Motley Fool•25 days ago
Better Buy: Geron Corporation vs. Incyte Corporation
The decision might not be as easy as it seems at first glance.
- GlobeNewswire•25 days ago
INVESTOR ALERT: Kaskela Law LLC Announces Investigation of Geron Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
RADNOR, Pa., Sept. 27, 2018-- Kaskela Law LLC is investigating claims on behalf of investors of Geron Corporation. The investigation concerns whether Geron and certain of its officers and/or directors ...
- Associated Press•25 days ago
Apple, Amazon and WellCare rise while Carnival skids
Stocks that moved substantially or traded heavily Thursday: Apple Inc., up $4.53 to $224.95 An analyst for JPMorgan Chase said Apple stock could rise more than 20 percent by late 2019. Carnival Corp., ...
- Motley Fool•25 days ago
Why Bed Bath & Beyond, Geron, and Canopy Growth Slumped Today
Find out how a marijuana stock made it onto this list.
InvestorPlace•25 days ago5 Top Stock Trades for Friday — BBBY, RAD and NFLX
In the first full trading session after the Fed decided to raise rates, the action wasn’t as clear-cut as it seemed during the first hours of the day. Tech popped, while the overall market moved higher. However, some of the air came out of those gains as the day went on, as stocks ended higher but with less conviction than in morning trade. Here are our top stock trades going into the end of the week.Top Stock Trades for Tomorrow #1: Bed Bath & Beyond (BBBY)
- PR Newswire•25 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN)
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Geron Corporation ("Geron" or ...
- PR Newswire•26 days ago
Investor Alert: Kaplan Fox Investigates Geron Corporation
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Menlo park, California -based Geron Corporation ("Geron" ...
- MarketWatch•26 days ago
Higher open puts stock market on track to halt multisession skid as traders absorb data, Fed hike
U.S. stock benchmarks opened tentatively higher Thursday as investors digested the Federal Reserve's third interest hike in 2018 at its Wednesday gathering and as Wall Street absorbed a wave of economic reports, including an update to second-quarter gross domestic product. The Dow Jones Industrial Average traded flat at 26,382, the S&P 500 index gained 0.1% at 2,910, while the Nasdaq Composite Index advanced 0.4% at 8,024. Markets slumped late Wednesday after the Fed lifted interest rates by a quarter-percentage point to a range of 2% to 2.25%, as expected, and signaled one more rate increase in December may be ahead. Meanwhile, investors watched a parade of data, including jobless claims, which rose less than expected in the latest week, though they remain near multidecade lows. Orders for durable goods rose 4.5%, faster than had been expected. U.S. real gross domestic product for the second quarter rose at a 4.2% annualized rate, unchanged from the earlier estimate, the Commerce Department said. In corporate news, shares of Geron Corp. plummeted after a collaboration deal with Janssen was terminated, as did those for Bed Bath & Beyond Inc. , which tumbled after it reported earnings and revenue that missed expectations. Wall Street may keep one eye trained on a Senate hearing of Supreme Court Justice nominee Brett Kavanaugh, who is contending with allegations of sexual misconduct.
- Bloomberg•26 days ago
Geron Plunges 68% After J&J Ends Partnership That Had Ignited Stock
A stellar year for Geron Corp. investors went up in smoke Thursday as shares plummeted on news that Johnson & Johnson will end a licensing partnership and return rights to the biotech company’s sole product candidate. Geron slid as much as 76 percent as the market opened, dropping to $1.99 at 9:44 a.m. in New York. The move wiped out $750 million in market value, which is more than the total value ascribed to a third of the companies in the Nasdaq Biotechnology Index.
